Investment to progress RheumaGen's celiac disease program through early development as a potential transformational gene therapy PHILADELPHIA, Dec. 22, 2025 /PRNewswire/ -- Beyond Celiac Investments ...

Investment to progress RheumaGen's celiac disease program through early development as a potential transformational gene therapy AURORA, Colo., Dec. 22, 2025 /PRNewswire/ -- RheumaGen, Inc., a cell ...

According to a recent study by researchers at the University of the Basque Country (EHU), raising social awareness is ...

The Gluten3S research group launched a dietary intervention with children who had recently been diagnosed with celiac disease ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an ...

The NIMA Gluten Sensor is 99% accurate at detecting gluten in your food. All it takes is three minutes. At CES 2026, one of ...

What started as occasional stomachaches and migraines for Valerie Kraft throughout her childhood turned into a decade-long ...

Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is in a ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-'408TEV-' ...

Researchers at Penn Medicine have developed an mRNA vaccine that could potentially cure allergies by stopping allergens from ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-'408 TE ...